Clinical Trial Update: A Valsartan 80 Mg-Referenced, Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan 30 mg During 24 Hours in Patients With Mild to Moderate Essential Hypertension [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluating the 24-hour antihypertensive efficacy of fimasartan 30 mg with valsartan 80 mg as reference has completed in patients with mild to…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Hypertension

Drugs mentioned

• Fimasartan (fimasartan)
• VALSARTAN (Valsartan)

Snippet

Sponsor: Boryung Pharmaceutical Co., Ltd | Conditions: Essential Hypertension | Phase 2 | Status: COMPLETED